OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
OCULAR THERAPEUTIX, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$6.29−0.58 (-8.44%)
Close on Oct 19, 2026
- Market cap
- $1.41B
- P/E (TTM)
- –
- Dividend yield
- –
OCULAR THERAPEUTIX, INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $51.82M | $63.46M | $57.87M | $50.46M | $43.52M | $17.40M | $1.99M | $1.92M | $1.85M | 99.8% | -18.3% |
| Collaboration revenue | $128.00K | $262.00K | $573.00K | $1.04M | – | – | – | – | $42.00K | 0.2% | -51.1% |
By region
From the segment and revenue-disaggregation notes of Ocular Therapeutix's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.